verapamil has been researched along with Cardiac Failure in 145 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CLINICAL TRIALS WITH VERAPAMIL AND TRANDOLAPRIL: In the Danish Verapamil Infarction Trial II, verapamil improved survival in patients without heart failure but had no effect in patients with heart failure who were receiving diuretic treatment." | 10.18 | Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. ( Hansen, JF, 1998) |
| ", death, repeat infarction, unstable angina pectoris, or repeat admission because of heart failure) was 14% in patients treated with verapamil and trandolapril and 35% in patients treated with trandolapril (p = 0." | 9.08 | Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. ( Bjergaard, OP; Hagerup, L; Hansen, JF; Mellemgaard, K; Pedersen, F; Sigurd, B, 1997) |
| "EFFECTS OF VERAPAMIL AND TRANDOLAPRIL: Progression of heart failure, sudden death and death from re-infarction are the major cause of the increased mortality in postinfarct patients with congestive heart failure." | 8.79 | Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). ( Hagerup, L; Hansen, JF; Mellemgaard, K; Pedersen, F; Pedersen-Bjergaard, O; Sigurd, B, 1997) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 7.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| "Levosimendan increased CO in this model of verapamil poisoning to a similar degree as CaCl2 alone, but it did not improve BP from time of maximal toxicity." | 7.74 | Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. ( Graudins, A; Najafi, J; Rur-SC, MP, 2008) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 7.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| " We report a case in which low-dose verapamil resulted in marked worsening of congestive heart failure, as a result of a profound negative inotropic effect." | 7.68 | Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. ( Falk, RH; Pollak, A, 1993) |
| "The role that the new antiarrhythmic agents, such as verapamil and amiodarone, might play in the therapeutic strategy of tachycardia-induced fetal heart failure remains to be determined." | 7.67 | Transplacental treatment of tachycardia-induced fetal heart failure with verapamil and amiodarone: a case report. ( Duperron, L; Gauthier, R; Grignon, A; LeLorier, J; Lemay, M; Rey, E, 1985) |
| " Therefore, intravenous diltiazem (100 to 200 micrograms/kg per min infusion) was administered for 40 minutes followed by oral diltiazem (90 to 120 mg/8 hours) for 24 hours to patients with advanced congestive heart failure (New York Heart Association class III to IV, mean ejection fraction 26 +/- 4 [SD])." | 7.67 | Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure. ( O'Rourke, RA; Porter, CB; Starling, MR; Walsh, RW, 1984) |
| "Amrinone, a positive inotropic-vasodilator agent, was administered to anaesthetised dogs in an attempt to reverse heart failure induced by drugs possessing negative inotropic properties." | 7.67 | The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetised dog. ( Alousi, AA; Canter, JM; Fort, DJ, 1985) |
| "Three infants with supraventricular tachycardia and congestive cardiac failure were given verapamil intravenously." | 7.67 | Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. ( Epstein, ML; Kiel, EA; Victorica, BE, 1985) |
| "Nifedipine was used successfully in nine patients with refractory hypertension and left ventricular hypertrophy who had symptoms of congestive heart failure despite preserved left ventricular systolic function." | 7.67 | Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. ( Dzau, VJ; Given, BD; Lee, TH; Stone, PH, 1985) |
| "In this study, observation of the effects of verapamil on pulmonary arterial pressure and on treating right heart failure were done in 15 patients with chronic cor pulmonale complicated with heart failure using monitoring of hemodynamic changes by right cardiac catheter." | 7.67 | [Effects of verapamil on pulmonary arterial pressure in patients with cor pulmonale complicated by heart failure]. ( Shan, ZY, 1989) |
| " A long-term, open clinical trial of verapamil therapy was conducted in ninety-three patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenoceptor blocking drugs." | 7.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1982) |
| "Because of its intrinsic negative inotropic effect, the administration of the recently introduced calcium antagonist, verapamil, is thought to be contraindicated in presence of congestive heart failure (CHF)." | 7.66 | Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure. ( Citron, PD; Ferlinz, J, 1983) |
| "Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter." | 6.82 | Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients? ( Bei, A; Calò, L; Cice, G; Di Lullo, L; Lido, P; Noce, A; Palazzetti, D; Perrone, MA; Romanello, D; Tesauro, M, 2022) |
| "In patients treated for heart failure during the acute phase of myocardial infarction, the lowest 18-month event rate was seen in the verapamil group (21." | 6.67 | The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM, 1993) |
| "CLINICAL TRIALS WITH VERAPAMIL AND TRANDOLAPRIL: In the Danish Verapamil Infarction Trial II, verapamil improved survival in patients without heart failure but had no effect in patients with heart failure who were receiving diuretic treatment." | 6.18 | Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. ( Hansen, JF, 1998) |
| ", death, repeat infarction, unstable angina pectoris, or repeat admission because of heart failure) was 14% in patients treated with verapamil and trandolapril and 35% in patients treated with trandolapril (p = 0." | 5.08 | Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. ( Bjergaard, OP; Hagerup, L; Hansen, JF; Mellemgaard, K; Pedersen, F; Sigurd, B, 1997) |
| "The Danish Verapamil Infarction Trial II (DAVIT II) demonstrated from the second postinfarction week, that long term treatment with verapamil significantly improved reinfarction free survival after an acute myocardial infarction (AMI)." | 5.08 | Effect of verapamil on the prognosis of patients with early postinfarction electrical or mechanical complications. The Danish Verapamil Infarction Trial II (DAVIT II). ( Hagerup, L; Hansen, JF; Mellemgaard, K; Sigurd, B; Steinmetz, E; Vaage-Nilsen, M, 1995) |
| " Patients suffering from congestive heart failure were treated with Digitalis, other patients with normal hearts were subjected to infusion therapy of Isoproterenol, Propranolol, Verapamil and Calcium chloride." | 5.04 | [Echocardiographic evaluation of left ventricular function during therapy with cardiovascularly effective drugs]. ( Stefan, G, 1976) |
| "The use of intravenous verapamil for tachyarrhythmia in infants is widely considered contraindicated due to the perceived risk of hemodynamic collapse after administration." | 4.89 | Verapamil in infants: an exaggerated fear? ( Bradley, DJ; Dick, M; Lapage, MJ, 2013) |
| "Trandolapril is a newer angiotensin-converting enzyme (ACE) inhibitor that is approved by the US Food and Drug Administration for the treatment of hypertension and for use in stable patients who have evidence of left ventricular (LV) systolic dysfunction or symptoms of chronic heart failure within the first 2 days after an acute myocardial infarction (AMI)." | 4.82 | Trandolapril: a newer angiotensin-converting enzyme inhibitor. ( Guay, DR, 2003) |
| "Digoxin, which has a very narrow therapeutic window, is one of the most commonly prescribed drugs in the treatment of congestive heart failure." | 4.80 | P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. ( Beijnen, JH; Koks, CH; Schellens, JH; Verschraagen, M, 1999) |
| "EFFECTS OF VERAPAMIL AND TRANDOLAPRIL: Progression of heart failure, sudden death and death from re-infarction are the major cause of the increased mortality in postinfarct patients with congestive heart failure." | 4.79 | Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). ( Hagerup, L; Hansen, JF; Mellemgaard, K; Pedersen, F; Pedersen-Bjergaard, O; Sigurd, B, 1997) |
| " Verapamil is extremely effective in patients with supraventricular tachyarrhythmias, hypertrophic cardiomyopathy, and the various anginal syndromes, but it appears to be ineffective or possibly even deleterious in those with pulmonary hypertension, congestive heart failure of any cause, and Raynaud's phenomenon or disease." | 4.77 | Calcium antagonists in patients with cardiovascular disease. Current perspectives. ( Hillis, LD; Winniford, MD, 1985) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 3.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| "Levosimendan increased CO in this model of verapamil poisoning to a similar degree as CaCl2 alone, but it did not improve BP from time of maximal toxicity." | 3.74 | Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. ( Graudins, A; Najafi, J; Rur-SC, MP, 2008) |
| "854(DFAC), where C(cr) is the estimated creatinine clearance (ml/min); CCB=1 for concomitant administration of calcium channel blockers and CCB=zero otherwise; CHF=1 for the patients with congestive heart failure and CHF=zero otherwise; SPI=1 for concomitant administration of spironolactone and SPI=zero otherwise; DFAC=1 for administration of a half-tablet of digoxin and DFAC=zero otherwise." | 3.71 | Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis. ( Goto, Y; Higuchi, S; Minemoto, M; Ohdo, S; Suematsu, F; Yukawa, E; Yukawa, M, 2002) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 3.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| "For the evaluation of the hemodynamic interaction between the natural heart and an assist device, a reversible pharmacological model based on the channel blocker Verapamil under hyperkalemia, was developed for deterioration of left ventricular function." | 3.69 | Pharmacologically induced heart failure for the evaluation of circulatory assistance. ( Losert, U; Roschal, K; Schima, H; Schmidt, C; Schwendenwein, I; Wieselthaler, G; Wolner, E, 1996) |
| "To review the safety and efficacy of verapamil and diltiazem with respect to ventricular response in atrial fibrillation (AF) in the setting of left ventricular (LV) systolic dysfunction." | 3.69 | Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure. ( Heywood, JT, 1995) |
| " We report a case in which low-dose verapamil resulted in marked worsening of congestive heart failure, as a result of a profound negative inotropic effect." | 3.68 | Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. ( Falk, RH; Pollak, A, 1993) |
| "Aside from its more conventional uses as a cardiovascular drug, the calcium channel blocker verapamil has recently been added to chemotherapeutic regimens to reduce drug resistance in B-cell and other neoplasms that express the P-glycoprotein." | 3.68 | Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. ( Appleton, CP; Dalton, WS; Miller, TP; Mosley, K; Pennock, GD; Plezia, P; Roeske, WR; Salmon, SE, 1991) |
| "Three infants with supraventricular tachycardia and congestive cardiac failure were given verapamil intravenously." | 3.67 | Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. ( Epstein, ML; Kiel, EA; Victorica, BE, 1985) |
| "A single administration of verapamil (5 mg infused intravenously) and nifedipin (20 mg sublingually) in 31 patients with chronic cardiac failure of stage I and IIA decreased the levels of ionizing calcium (Ca2+) in the blood serum (the maximum reduction averaged 19." | 3.67 | [Effect of verapamil and nifedipine on the fractional composition of calcium in the blood serum]. ( Merzon, KA, 1985) |
| ") was effective in heart failure models induced with high doses of propranolol or verapamil." | 3.67 | Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. ( Kitada, Y; Narimatsu, A; Okushima, H; Satoh, N; Suzuki, R, 1987) |
| "Nifedipine was used successfully in nine patients with refractory hypertension and left ventricular hypertrophy who had symptoms of congestive heart failure despite preserved left ventricular systolic function." | 3.67 | Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. ( Dzau, VJ; Given, BD; Lee, TH; Stone, PH, 1985) |
| "In this study, observation of the effects of verapamil on pulmonary arterial pressure and on treating right heart failure were done in 15 patients with chronic cor pulmonale complicated with heart failure using monitoring of hemodynamic changes by right cardiac catheter." | 3.67 | [Effects of verapamil on pulmonary arterial pressure in patients with cor pulmonale complicated by heart failure]. ( Shan, ZY, 1989) |
| "As many as 52 patients with essential hypertension aggravated by circulatory failure were examined for the clinical, hemodynamic and neurohumoral parameters during furosemide stimulation." | 3.67 | [The efficacy of calcium antagonists in circulatory failure in elderly patients with hypertension]. ( Orynchak, MA, 1989) |
| "Amrinone, a positive inotropic-vasodilator agent, was administered to anaesthetised dogs in an attempt to reverse heart failure induced by drugs possessing negative inotropic properties." | 3.67 | The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetised dog. ( Alousi, AA; Canter, JM; Fort, DJ, 1985) |
| "The role that the new antiarrhythmic agents, such as verapamil and amiodarone, might play in the therapeutic strategy of tachycardia-induced fetal heart failure remains to be determined." | 3.67 | Transplacental treatment of tachycardia-induced fetal heart failure with verapamil and amiodarone: a case report. ( Duperron, L; Gauthier, R; Grignon, A; LeLorier, J; Lemay, M; Rey, E, 1985) |
| " Therefore, intravenous diltiazem (100 to 200 micrograms/kg per min infusion) was administered for 40 minutes followed by oral diltiazem (90 to 120 mg/8 hours) for 24 hours to patients with advanced congestive heart failure (New York Heart Association class III to IV, mean ejection fraction 26 +/- 4 [SD])." | 3.67 | Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure. ( O'Rourke, RA; Porter, CB; Starling, MR; Walsh, RW, 1984) |
| "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs." | 3.66 | Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases. ( Anderson, ST; Federman, J; Harper, RW; Laufer, E; Pitt, A; Wayne, VS, 1982) |
| "Clinical experience with calcium antagonists in congestive heart failure has, to date, been mainly restricted to the use of nifedipine but there is either no or only a limited extent of information available on diltiazem and verapamil." | 3.66 | Calcium antagonists in heart failure. ( Camerini, F; Klugmann, S; Salvi, A, 1983) |
| "Because of its intrinsic negative inotropic effect, the administration of the recently introduced calcium antagonist, verapamil, is thought to be contraindicated in presence of congestive heart failure (CHF)." | 3.66 | Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure. ( Citron, PD; Ferlinz, J, 1983) |
| " A long-term, open clinical trial of verapamil therapy was conducted in ninety-three patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenoceptor blocking drugs." | 3.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1982) |
| "Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter." | 2.82 | Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients? ( Bei, A; Calò, L; Cice, G; Di Lullo, L; Lido, P; Noce, A; Palazzetti, D; Perrone, MA; Romanello, D; Tesauro, M, 2022) |
| "In patients treated for heart failure during the acute phase of myocardial infarction, the lowest 18-month event rate was seen in the verapamil group (21." | 2.67 | The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM, 1993) |
| "Because sudden cardiac death is the most serious complication of HCM, particularly in young and asymptomatic patients, it follows that correct diagnosis, followed by risk stratification of patients with regard to the need for prophylactic implantation of an implantable cardiac defibrillator (ICD), can be of life-saving importance." | 2.47 | The diagnosis and treatment of hypertrophic cardiomyopathy. ( Faber, L; Farr, M; Hering, D; Horstkotte, D; Prinz, C, 2011) |
| "Patients with heart failure are particularly susceptible to the negative effects of calcium channel blockers because the failing heart demonstrates a defect in the delivery of calcium to the contractile proteins, and an attenuation of the normal sympathetic reflexes." | 2.40 | [Calcium channel blockers in heart failure]. ( Dickstein, K; Gundersen, T; Hole, T; Kjekshus, J; Myhre, ES; Rønnevik, PK; Westheim, AS, 1997) |
| "Ventricular arrhythmias are significantly associated with arrhythmic as well as non-arrhythmic death." | 2.39 | Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. ( Jespersen, CM, 1996) |
| "Digoxin was given both to the mother and to the fetus." | 2.38 | [Hydrops fetalis in tachycardia: diagnostic and therapeutic procedures]. ( Arbenz, U; Baumann, H; Dudenhausen, J; Huch, A; Karrer, G; Vetter, K, 1990) |
| "Even verapamil, however, has been shown to lead to hemodynamic improvement in some patients, at least after acute administration." | 2.38 | [Treatment of heart failure with calcium antagonists]. ( Dirschinger, J; Hall, D; Kraus, F; Rudolph, W, 1990) |
| "These effects of hyperoxia are prevented by vitamin C, providing evidence that hyperoxia-derived free radicals impair the activity of endothelium-derived vasoactive factors." | 1.31 | Vitamin C prevents hyperoxia-mediated vasoconstriction and impairment of endothelium-dependent vasodilation. ( Colman, R; Egri, Z; Mak, S; Newton, GE; Tanna, G, 2002) |
| "Dantrolene sodium is a clinically used drug that modulates myocardial [Ca2+]i handling in animal models." | 1.30 | Dantrolene sodium improves the force-frequency relationship and beta-adregenic responsiveness in failing human myocardium. ( Haake, N; Hirt, S; Meissner, A; Min, JY; Simon, R, 1999) |
| "The treatment with verapamil led to a normal rhythm and function of the heart." | 1.30 | [Verapamil sensitive ventricular tachycardia with myocardial failure in a 2-year-old child]. ( Gossen, N; Liersch, R; Ulbricht, LJ; Winter, K, 1999) |
| "Digoxin activity was measured on the eighth, ninth and sixteenth day of treatment by Rubidium 86 uptake in erythrocytes." | 1.27 | [Increased digitalis-like activity in combined administration of calcium antagonists and digitalis preparations]. ( Balestrazzi, M; Chiarappa, R; De Cesaris, R; Ranieri, G, 1983) |
| "Diltiazem was not significantly different from placebo." | 1.27 | Comparative effects of calcium-channel blocking agents on left ventricular function during acute ischemia in dogs with and without congestive heart failure. ( Epstein, SE; Patterson, RE; Urquhart, J, 1985) |
| "In half of the patients with tachyarrhythmia." | 1.26 | [Treatment of acute left-ventricular insufficiency complicated by tachyarrhythmia under conditions of cardiological emergency service]. ( Danilenko, AM; Rodionov, VM; Zakharova, RM, 1979) |
| " The dosage varied according to the weight of the infant." | 1.26 | Effect of verapamil in infants with paroxysmal supraventricular tachycardia. ( Cabrera, A; Iglesias-Berengué, J; Permanyer-Miralda, G; Roca-Llop, J; Sagristá-Sauleda, J; Sauleda-Parés, J; Soler-Soler, J, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 73 (50.34) | 18.7374 |
| 1990's | 44 (30.34) | 18.2507 |
| 2000's | 12 (8.28) | 29.6817 |
| 2010's | 13 (8.97) | 24.3611 |
| 2020's | 3 (2.07) | 2.80 |
| Authors | Studies |
|---|---|
| Lido, P | 1 |
| Romanello, D | 1 |
| Tesauro, M | 1 |
| Bei, A | 1 |
| Perrone, MA | 1 |
| Palazzetti, D | 1 |
| Noce, A | 1 |
| Di Lullo, L | 1 |
| Calò, L | 1 |
| Cice, G | 1 |
| Meyer, M | 1 |
| Wetmore, JB | 1 |
| Weinhandl, ED | 1 |
| Roetker, NS | 1 |
| Liu, J | 2 |
| Liu, Y | 1 |
| Yu, H | 1 |
| Zhang, Y | 1 |
| Hsu, AC | 1 |
| Zhang, M | 1 |
| Gou, Y | 1 |
| Sun, W | 1 |
| Wang, F | 1 |
| Li, P | 1 |
| Lapage, MJ | 1 |
| Bradley, DJ | 1 |
| Dick, M | 1 |
| Speerschneider, T | 1 |
| Thomsen, MB | 1 |
| Déniel, A | 1 |
| Fedrizzi, S | 1 |
| Lelong-Boulouard, V | 1 |
| Coquerel, A | 1 |
| Alexandre, J | 1 |
| Kanorskii, SG | 1 |
| Sereda, AF | 1 |
| Ertunc, M | 1 |
| Sara, Y | 1 |
| Korkusuz, P | 1 |
| Onur, R | 1 |
| Kijtawornrat, A | 1 |
| Ziolo, MT | 1 |
| Nishijima, Y | 1 |
| Roche, BM | 1 |
| Hamlin, RL | 1 |
| Prinz, C | 1 |
| Farr, M | 1 |
| Hering, D | 1 |
| Horstkotte, D | 1 |
| Faber, L | 1 |
| Oghlakian, GO | 1 |
| Sipahi, I | 1 |
| Fang, JC | 1 |
| Milberg, P | 2 |
| Fink, M | 1 |
| Pott, C | 1 |
| Frommeyer, G | 2 |
| Biertz, J | 1 |
| Osada, N | 1 |
| Stypmann, J | 1 |
| Mönnig, G | 1 |
| Koopmann, M | 1 |
| Breithardt, G | 1 |
| Eckardt, L | 2 |
| Stams, TR | 1 |
| Bourgonje, VJ | 1 |
| Vos, MA | 1 |
| van der Heyden, MA | 1 |
| Raake, PW | 1 |
| Zhang, X | 1 |
| Vinge, LE | 1 |
| Brinks, H | 1 |
| Gao, E | 1 |
| Jaleel, N | 1 |
| Li, Y | 1 |
| Tang, M | 1 |
| Most, P | 1 |
| Dorn, GW | 1 |
| Houser, SR | 2 |
| Katus, HA | 1 |
| Chen, X | 1 |
| Koch, WJ | 1 |
| Krishnamurthy, K | 1 |
| Vedam, K | 1 |
| Kanagasabai, R | 1 |
| Druhan, LJ | 1 |
| Ilangovan, G | 1 |
| Stengaard, C | 1 |
| Eiskjær, H | 1 |
| Jensen, HK | 1 |
| Suematsu, F | 1 |
| Yukawa, E | 1 |
| Yukawa, M | 1 |
| Minemoto, M | 1 |
| Ohdo, S | 1 |
| Higuchi, S | 1 |
| Goto, Y | 2 |
| Sidorenko, GI | 1 |
| Ostrovskiĭ, IuP | 1 |
| Guay, DR | 1 |
| Gurevich, MA | 1 |
| Graudins, A | 1 |
| Najafi, J | 1 |
| Rur-SC, MP | 1 |
| Opie, LH | 1 |
| Wayne, VS | 1 |
| Harper, RW | 1 |
| Laufer, E | 1 |
| Federman, J | 1 |
| Anderson, ST | 1 |
| Pitt, A | 1 |
| Krikler, DM | 1 |
| Rowland, E | 1 |
| Theisen, K | 1 |
| Ellrodt, AG | 1 |
| Singh, BN | 1 |
| Sloan, RW | 1 |
| Moret, P | 1 |
| Guazzi, MD | 1 |
| Cipolla, C | 1 |
| Della Bella, P | 1 |
| Fabbiocchi, F | 1 |
| Montorsi, P | 1 |
| Sganzerla, P | 1 |
| Gracián Gómez, M | 1 |
| Rodríguez Caamaño, J | 1 |
| Guía Torrent, JM | 1 |
| Benjamin, GC | 1 |
| Brandt, D | 1 |
| Hill, LM | 1 |
| Breckle, R | 1 |
| Driscoll, DJ | 1 |
| De Cesaris, R | 1 |
| Balestrazzi, M | 1 |
| Chiarappa, R | 1 |
| Ranieri, G | 1 |
| Walsh, RW | 1 |
| Porter, CB | 1 |
| Starling, MR | 1 |
| O'Rourke, RA | 2 |
| Klein, HO | 1 |
| Kaplinsky, E | 1 |
| Lessem, J | 1 |
| Raftos, J | 1 |
| Kopman, EA | 1 |
| Ferlinz, J | 1 |
| Citron, PD | 1 |
| Klugmann, S | 1 |
| Salvi, A | 1 |
| Camerini, F | 2 |
| Polverino, W | 1 |
| Basso, A | 1 |
| Muto, P | 1 |
| Genovese, A | 1 |
| Perrone, V | 1 |
| Apice, G | 1 |
| Farace, J | 1 |
| Tkaczewski, W | 1 |
| Goch, JH | 1 |
| Wichan, P | 1 |
| Kowalski, J | 1 |
| Hansen, JF | 8 |
| Sigurd, B | 5 |
| Mellemgaard, K | 6 |
| Lyngbye, J | 1 |
| Low, RI | 1 |
| Takeda, P | 1 |
| Mason, DT | 1 |
| DeMaria, AN | 1 |
| Brener, Y | 1 |
| Kauli, N | 1 |
| Shahar, E | 1 |
| Barzilay, Z | 1 |
| Frand, M | 1 |
| Gras, D | 1 |
| Daubert, C | 1 |
| Mabo, P | 1 |
| Heywood, JT | 1 |
| Slater, JP | 1 |
| Lipsitz, EC | 1 |
| Chen, JM | 1 |
| Levin, HR | 1 |
| Oz, MC | 1 |
| Burkhoff, D | 1 |
| Jespersen, CM | 4 |
| Vaage-Nilsen, M | 1 |
| Hagerup, L | 5 |
| Steinmetz, E | 2 |
| Patel, R | 1 |
| Lipper, B | 1 |
| Schwartzbard, A | 1 |
| Nelson, C | 1 |
| O'Connor, MA | 1 |
| Frishman, W | 1 |
| Sterz, R | 1 |
| Salerno, SM | 1 |
| Zugibe, FT | 1 |
| Pollak, A | 1 |
| Falk, RH | 1 |
| Elkayam, U | 1 |
| Shotan, A | 1 |
| Mehra, A | 1 |
| Ostrzega, E | 1 |
| Holländer, N | 1 |
| Hven, PE | 1 |
| Launbjerg, J | 1 |
| Linde, NC | 1 |
| Nielsen, J | 1 |
| Herbert, ME | 1 |
| Votey, SR | 1 |
| Rutz, F | 1 |
| Schmidt, C | 1 |
| Schwendenwein, I | 1 |
| Wieselthaler, G | 1 |
| Roschal, K | 1 |
| Schima, H | 1 |
| Losert, U | 1 |
| Wolner, E | 1 |
| Pedersen, F | 3 |
| Pedersen-Bjergaard, O | 2 |
| Mortensen, LS | 1 |
| Park, S | 1 |
| McCune, SA | 1 |
| Radin, MJ | 1 |
| Hoepf, TM | 1 |
| Hensley, J | 1 |
| Hohl, CM | 1 |
| Altschuld, RA | 1 |
| Hole, T | 1 |
| Dickstein, K | 1 |
| Gundersen, T | 1 |
| Kjekshus, J | 1 |
| Myhre, ES | 1 |
| Rønnevik, PK | 1 |
| Westheim, AS | 1 |
| Bjergaard, OP | 1 |
| Suzuki, M | 1 |
| Cheng, CP | 1 |
| Ohte, N | 1 |
| Little, WC | 1 |
| White, CM | 1 |
| Winter, K | 1 |
| Gossen, N | 1 |
| Ulbricht, LJ | 1 |
| Liersch, R | 1 |
| Verschraagen, M | 1 |
| Koks, CH | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Marín Ortuño, F | 1 |
| Picó Alfonso, AM | 1 |
| Martínez Martínez, JG | 1 |
| Domínguez Escribano, JR | 1 |
| Sogorb Garri, F | 1 |
| Wasserstrom, JA | 1 |
| Holt, E | 1 |
| Sjaastad, I | 1 |
| Lunde, PK | 1 |
| Odegaard, A | 1 |
| Sejersted, OM | 1 |
| Meissner, A | 1 |
| Min, JY | 1 |
| Haake, N | 1 |
| Hirt, S | 1 |
| Simon, R | 1 |
| Neglia, D | 1 |
| Sambuceti, G | 1 |
| Giorgetti, A | 1 |
| Bartoli, M | 1 |
| Salvadori, P | 1 |
| Sorace, O | 1 |
| Puccini, G | 1 |
| L'Abbate, A | 1 |
| Parodi, O | 1 |
| Sandmann, S | 1 |
| Claas, R | 1 |
| Cleutjens, JP | 1 |
| Daemen, MJ | 1 |
| Unger, T | 1 |
| Feldman, J | 1 |
| Laxer, I | 1 |
| Yaretzky, A | 1 |
| Kodama-Takahashi, K | 1 |
| Ohshima, K | 1 |
| Yamamoto, K | 1 |
| Iwata, T | 1 |
| Piacentino, V | 1 |
| Gaughan, JP | 1 |
| Mak, S | 1 |
| Egri, Z | 1 |
| Tanna, G | 1 |
| Colman, R | 1 |
| Newton, GE | 1 |
| Anschütz, F | 1 |
| Witchitz, S | 1 |
| Haiat, R | 1 |
| Tarrade, T | 1 |
| Chiche, P | 1 |
| Bouzo, H | 1 |
| Soler-Soler, J | 1 |
| Sagristá-Sauleda, J | 1 |
| Cabrera, A | 1 |
| Sauleda-Parés, J | 1 |
| Iglesias-Berengué, J | 1 |
| Permanyer-Miralda, G | 1 |
| Roca-Llop, J | 1 |
| Danilenko, AM | 1 |
| Rodionov, VM | 1 |
| Zakharova, RM | 1 |
| Campa, PP | 1 |
| Speca, G | 1 |
| De Curtis, G | 1 |
| Pecce, P | 1 |
| Stefan, G | 1 |
| Wolf, R | 1 |
| Nötges, A | 1 |
| Witt, E | 1 |
| Habel, F | 1 |
| Everling, F | 1 |
| Hochrein, H | 1 |
| Arstall, MA | 1 |
| Beltrame, JF | 1 |
| Mohan, P | 1 |
| Wuttke, RD | 1 |
| Esterman, AJ | 1 |
| Horowitz, JD | 1 |
| Podszus, Th | 1 |
| Peter, JH | 1 |
| Völger, KD | 1 |
| Zilles, P | 1 |
| Moser, C | 1 |
| Risse, N | 1 |
| Langer, HJ | 1 |
| Fröhlig, G | 1 |
| Volkmer, I | 1 |
| Hinkeldey, K | 1 |
| Weinges, KF | 1 |
| Clozel, JP | 1 |
| Véniant, M | 1 |
| Osterrieder, W | 1 |
| Pennock, GD | 1 |
| Dalton, WS | 1 |
| Roeske, WR | 1 |
| Appleton, CP | 1 |
| Mosley, K | 1 |
| Plezia, P | 1 |
| Miller, TP | 1 |
| Salmon, SE | 1 |
| Schwinger, RH | 1 |
| Böhm, M | 1 |
| Erdmann, E | 1 |
| Karrer, G | 1 |
| Baumann, H | 1 |
| Vetter, K | 1 |
| Dudenhausen, J | 1 |
| Huch, A | 1 |
| Arbenz, U | 1 |
| Hall, D | 1 |
| Dirschinger, J | 1 |
| Kraus, F | 1 |
| Rudolph, W | 1 |
| Setaro, JF | 1 |
| Zaret, BL | 1 |
| Schulman, DS | 1 |
| Black, HR | 1 |
| Soufer, R | 1 |
| Gorb, IuG | 1 |
| Seab, KhK | 1 |
| Mikliaev, IIu | 1 |
| Capasso, JM | 2 |
| Sonnenblick, EH | 2 |
| Anversa, P | 1 |
| Chizh, VD | 1 |
| Ilan, Y | 1 |
| Hillman, M | 1 |
| Oren, R | 1 |
| Frisolone, JA | 1 |
| Orynchak, MA | 3 |
| Shan, ZY | 1 |
| Mohindra, SK | 1 |
| Udeani, GO | 1 |
| Vintzileos, AM | 1 |
| Campbell, WA | 1 |
| Soberman, SM | 1 |
| Nochimson, DJ | 1 |
| Barbieri, L | 1 |
| Mestroni, L | 1 |
| Given, BD | 1 |
| Lee, TH | 1 |
| Stone, PH | 1 |
| Dzau, VJ | 1 |
| Maxwell, DJ | 1 |
| Crawford, DC | 1 |
| Curry, PV | 1 |
| Tynan, MJ | 1 |
| Allan, LD | 1 |
| Baughman, KL | 1 |
| Larach, DR | 1 |
| Zelis, R | 1 |
| Kendall, MJ | 1 |
| Horton, RC | 1 |
| Smith, SR | 1 |
| Lauterburg, BH | 1 |
| Narimatsu, A | 1 |
| Kitada, Y | 1 |
| Satoh, N | 1 |
| Suzuki, R | 1 |
| Okushima, H | 1 |
| Kanemoto, N | 1 |
| Satoh, M | 1 |
| Tagawa, R | 1 |
| Bjørnstad, PG | 1 |
| Storstein, L | 1 |
| Semb, BK | 1 |
| Merzon, KA | 2 |
| Doviner, AD | 1 |
| Zolotov, NA | 1 |
| Kolomiets, VV | 1 |
| Kiriaev, AA | 1 |
| Drexler, H | 1 |
| Just, H | 1 |
| Walsh, RA | 1 |
| Winniford, MD | 1 |
| Hillis, LD | 1 |
| Fein, F | 1 |
| Factor, SM | 1 |
| Bergmans, MG | 1 |
| Jonker, GJ | 1 |
| Kock, HC | 1 |
| Schroeder, JS | 1 |
| Wikman-Coffelt, J | 1 |
| Sievers, R | 1 |
| Parmley, WW | 1 |
| Jasmin, G | 1 |
| Urquhart, J | 1 |
| Epstein, SE | 1 |
| Patterson, RE | 1 |
| Epstein, ML | 1 |
| Kiel, EA | 1 |
| Victorica, BE | 1 |
| Alousi, AA | 1 |
| Canter, JM | 1 |
| Fort, DJ | 1 |
| Akhmedkhanov, SSh | 1 |
| Pomerantsev, VP | 1 |
| Basiuk, IuA | 1 |
| Rey, E | 1 |
| Duperron, L | 1 |
| Gauthier, R | 1 |
| Lemay, M | 1 |
| Grignon, A | 1 |
| LeLorier, J | 1 |
| Brisse, B | 1 |
| Bräuer, B | 1 |
| Müller, W | 1 |
| Gradaus, D | 1 |
| Bender, F | 1 |
| Bernauer, W | 1 |
| Schanz, HM | 1 |
| Rippert, C | 1 |
| Hüter, J | 1 |
| Bärtschi, R | 1 |
| Grossmann, D | 1 |
| Mishra, BR | 1 |
| Adjan, M | 1 |
| Heck, J | 1 |
| Heim, RR | 1 |
| Elbers, C | 1 |
| Brichard, G | 1 |
| Zimmermann, PE | 1 |
| Eisel, K | 1 |
| Kaiser, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction[NCT03837470] | Early Phase 1 | 14 participants (Actual) | Interventional | 2019-05-06 | Completed | ||
| Regional and Systemic Hemodynamic Effects of a Long-term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin[NCT00151619] | Phase 2 | 7 participants (Actual) | Interventional | 1999-02-10 | Terminated | ||
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
30 reviews available for verapamil and Cardiac Failure
| Article | Year |
|---|---|
Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?
Topics: Cardio-Renal Syndrome; Diabetes Mellitus; Diabetic Nephropathies; Female; Heart Failure; Humans; Hyp | 2022 |
Verapamil in infants: an exaggerated fear?
Topics: Calcium Channel Blockers; Global Health; Health Knowledge, Attitudes, Practice; Heart Failure; Hemod | 2013 |
The diagnosis and treatment of hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Cardiac Surgical Procedures; Cardiomyopathy, Hypertr | 2011 |
Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2011 |
Calcium handling and ventricular tachyarrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Calcium Channels, L-Type; Electrocardiography; Heart Failu | 2012 |
[The no-reflow phenomenon and its clinical significance].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Atherectomy; Coronary Angiography; Coronary Artery Bypass | 2002 |
Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as | 2003 |
Clinical value of calcium antagonists in treatment of cardiovascular disorders.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calciu | 1983 |
Clinical applications of slow channel blocking compounds.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Platelets; Blood Vessels; Calcium | 1983 |
[Use of calcium antagonists in the treatment of cardiac insufficiency].
Topics: Adult; Aged; Calcium Channel Blockers; Diltiazem; Heart Failure; Humans; Middle Aged; Nifedipine; Ve | 1984 |
[Recent advances and future perspectives in the medical treatment of cardiopathies in children].
Topics: Child; Ductus Arteriosus, Patent; Heart Defects, Congenital; Heart Failure; Humans; Hypoxia; Indomet | 1984 |
Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction.
Topics: Action Potentials; Administration, Oral; Atrial Fibrillation; Atrioventricular Node; Autonomic Nervo | 1982 |
[Value of cardiac pacing in hypertrophic obstructive cardiomyopathy refractory to medical treatment].
Topics: Adrenergic beta-Antagonists; Atrioventricular Node; Cardiac Pacing, Artificial; Female; Heart Conduc | 1995 |
Calcium channel blockers in heart failure.
Topics: Calcium Channel Blockers; Diltiazem; Heart Failure; Hemodynamics; Humans; Nifedipine; Verapamil | 1993 |
Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil.
Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Disease; Heart Failure; Humans; Myocardial | 1996 |
Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group).
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinica | 1997 |
[Calcium channel blockers in heart failure].
Topics: Calcium Channel Blockers; Dihydropyridines; Diltiazem; Heart Failure; Humans; Ventricular Dysfunctio | 1997 |
Calcium channel blockers in left ventricular dysfunction or congestive heart failure.
Topics: Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Felodipine; Heart Failure | 1997 |
Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinica | 1998 |
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
Topics: Animals; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiotoni | 1999 |
[Hydrops fetalis in tachycardia: diagnostic and therapeutic procedures].
Topics: Adult; Digoxin; Drug Therapy, Combination; Female; Heart Failure; Heart Rate, Fetal; Humans; Hydrops | 1990 |
[Treatment of heart failure with calcium antagonists].
Topics: Calcium Channel Blockers; Diltiazem; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Ni | 1990 |
[Calcium antagonists in congestive heart failure].
Topics: Calcium Channel Blockers; Cardiomyopathy, Dilated; Diltiazem; Felodipine; Heart Failure; Hemodynamic | 1988 |
Calcium channel blocking agents in congestive heart failure.
Topics: Administration, Oral; Biological Transport; Calcium; Calcium Channel Blockers; Cardiac Output; Cardi | 1986 |
Advances in calcium blocker therapy.
Topics: Arrhythmias, Cardiac; Arteriosclerosis; Asthma; Blood Platelet Disorders; Calcium; Calcium Channel B | 1986 |
Calcium antagonists and chronic cardiac failure.
Topics: Calcium Channel Blockers; Chronic Disease; Diltiazem; Heart Failure; Humans; Nifedipine; Verapamil | 1986 |
Calcium antagonists in patients with cardiovascular disease. Current perspectives.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Benzazepines; Cardio | 1985 |
Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy.
Topics: Animals; Cardiomyopathies; Cardiomyopathy, Hypertrophic; Coronary Vasospasm; Cricetinae; Heart Failu | 1985 |
Fetal supraventricular tachycardia. Review of the literature.
Topics: Adult; Cesarean Section; Digitalis; Drug Therapy, Combination; Electric Countershock; Electrocardiog | 1985 |
Combination therapy with isosorbide dinitrate: current status and the future.
Topics: Angina Pectoris; Coronary Vasospasm; Diltiazem; Drug Therapy, Combination; Esophageal Achalasia; Exe | 1985 |
18 trials available for verapamil and Cardiac Failure
| Article | Year |
|---|---|
Disparate unloading efficacy of the calcium channel blockers, verapamil and nifedipine, on the failing hypertensive left ventricle.
Topics: Cardiac Output; Clinical Trials as Topic; Echocardiography; Female; Heart Failure; Heart Ventricles; | 1984 |
Radionuclide evaluation of CHF.
Topics: Adolescent; Adult; Coronary Disease; Digoxin; Female; Heart Aneurysm; Heart Failure; Hemodynamics; H | 1981 |
[Ergometric test in sympatheticotonia after administration of propranolol, pindolol, verapamil and oxazepam].
Topics: Adolescent; Adrenergic Fibers; Adult; Clinical Trials as Topic; Exercise Test; Heart; Heart Failure; | 1980 |
Verapamil in acute myocardial infarction.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Heart Block; Heart Failure; Humans; Male; Middle Aged | 1980 |
Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Angina Pectoris; Computer Communication Networks; Double-Blind Method; Heart Failure; Humans; Myocar | 1994 |
Effect of verapamil on the prognosis of patients with early postinfarction electrical or mechanical complications. The Danish Verapamil Infarction Trial II (DAVIT II).
Topics: Aged; Arrhythmias, Cardiac; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; M | 1995 |
Does exercise-induced ST-segment depression predict benefit of medical intervention in patients recovering from acute myocardial infarction? The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Aged; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Heart Failure; Humans; Male; Mi | 1993 |
The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Denmark; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; | 1993 |
Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Denmark; Diuretics; Double | 1997 |
Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial.
Topics: Adult; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diuretic | 1997 |
Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinica | 1998 |
Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure.
Topics: Calcium Channel Blockers; Cardiac Output; Cardiomyopathy, Dilated; Coronary Circulation; Double-Blin | 2000 |
[Clinical experience in the treatment of cardiac insufficiencies].
Topics: Biological Availability; Clinical Trials as Topic; Digoxin; Drug Combinations; Heart Failure; Humans | 1977 |
[Echocardiographic evaluation of left ventricular function during therapy with cardiovascularly effective drugs].
Topics: Digoxin; Echocardiography; Heart; Heart Failure; Heart Ventricles; Humans; Isoproterenol; Propranolo | 1976 |
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.
Topics: Aged; Blood Pressure; Diastole; Double-Blind Method; Echocardiography; Exercise Test; Heart Failure; | 1990 |
[The effect of calcium antagonists on the hemodynamic function in patients with heart failure].
Topics: Calcium Channel Blockers; Cardiography, Impedance; Coronary Disease; Echocardiography; Heart Failure | 1990 |
[New viewpoints on the effect of beta-receptor blockaders].
Topics: Adrenergic beta-Antagonists; Alprenolol; Clinical Trials as Topic; Heart Failure; Humans; Male; Nore | 1973 |
[Gradulon in the treatment of heart insufficiency with simultaneous cardiocirculatory load].
Topics: Adult; Benzoates; Cardiovascular System; Clinical Trials as Topic; Digoxin; Drug Combinations; Drug | 1974 |
98 other studies available for verapamil and Cardiac Failure
| Article | Year |
|---|---|
Association of Nondihydropyridine Calcium Channel Blockers Versus β-Adrenergic Receptor Blockers With Risk of Heart Failure Hospitalization.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Heart F | 2023 |
Design, synthesis and biological evaluation of novel pyxinol derivatives with anti-heart failure activity.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Disease Models, Animal; Drug Design; E | 2021 |
Physiology and analysis of the electrocardiographic T wave in mice.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal | 2013 |
Fatal Cardiac Arrest Associated with Concomitant Bisoprolol and Verapamil Overdose.
Topics: Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Calcium Channel Blockers; Drug Overdose; Ech | 2016 |
[Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease].
Topics: Aged; Amlodipine; Antihypertensive Agents; Echocardiography; Exercise Tolerance; Female; Heart Failu | 2016 |
Differential contractile impairment of fast- and slow-twitch skeletal muscles in a rat model of doxorubicin-induced congestive heart failure.
Topics: Action Potentials; Animals; Caffeine; Disease Models, Animal; Doxorubicin; Heart Failure; Male; Memb | 2009 |
Effects of sarcolemmal Ca(2+) entry, ryanodine function, and kinase inhibitors on a rabbit model of heart failure.
Topics: Animals; Anti-Arrhythmia Agents; Benzylamines; Disease Models, Animal; Heart Failure; Isoquinolines; | 2010 |
Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure.
Topics: Action Potentials; Animals; Calcium; Calcium Channel Blockers; Erythromycin; Female; Heart; Heart Fa | 2012 |
Verapamil as an antiarrhythmic agent in congestive heart failure: hopping from rabbit to human?
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Heart Failure; Humans; Rabbits; Verapamil | 2012 |
Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cycl | 2012 |
Heat shock factor-1 knockout induces multidrug resistance gene, MDR1b, and enhances P-glycoprotein (ABCB1)-based drug extrusion in the heart.
Topics: Analysis of Variance; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette S | 2012 |
[Fulminant acute heart failure following intravenous bolus administration of verapamil in a patient with supraventricular tachycardia].
Topics: Administration, Intravenous; Adult; Calcium Channel Blockers; Electrocardiography; Heart Failure; Hu | 2013 |
Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Calcium Channel Blockers; Creatinine; Digoxi | 2002 |
[Characteristic features of the pathogenesis and treatment of coronary heart diseases, heart failure and arterial hypertension in patients with diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Glucose; Calcium Channel Blockers; Clinical Trial | 2005 |
Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
Topics: Animals; Antidotes; Blood Pressure; Calcium Chloride; Cardiac Output; Disease Models, Animal; Heart | 2008 |
Drugs and the heart. III. Calcium antagonists.
Topics: Angina Pectoris; Aniline Compounds; Arrhythmias, Cardiac; Calcium; Cardiomegaly; Diuretics; Heart Di | 1980 |
Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Coronary Disease; Drug Interactions; Drug Therapy, C | 1982 |
[Pharmacotherapy of paroxysmal tachycardia].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Disopyramide | 1983 |
Atrial fibrillation.
Topics: Age Factors; Aged; Atrial Fibrillation; Cardiomegaly; Digoxin; Electric Countershock; Electrocardiog | 1982 |
Cardiogenic pulmonary edema.
Topics: Aminophylline; Cardiovascular Agents; Digoxin; Diuretics; Dobutamine; Dopamine; Heart Failure; Human | 1984 |
[The hypertensive crisis].
Topics: Acute Disease; Calcium Channel Blockers; Clonidine; Coronary Disease; Diazoxide; Dihydralazine; Dilt | 1984 |
Sonographic evaluation of prenatal therapy for fetal supraventricular tachycardia and congestive heart failure. A case report.
Topics: Adult; Animals; Digoxin; Dogs; Female; Fetal Diseases; Heart Failure; Humans; Infant, Newborn; Pregn | 1983 |
[Increased digitalis-like activity in combined administration of calcium antagonists and digitalis preparations].
Topics: Aged; Digoxin; Drug Interactions; Drug Therapy, Combination; Heart Failure; Humans; Medigoxin; Middl | 1983 |
Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure.
Topics: Administration, Oral; Adult; Benzazepines; Diltiazem; Female; Heart Failure; Heart Rate; Hemodynamic | 1984 |
Verapamil in the long-term treatment of angina pectoris.
Topics: Angina Pectoris; Bradycardia; Calcium Channel Blockers; Constipation; Coronary Disease; Dose-Respons | 1982 |
Intravenous verapamil to relieve pulmonary congestion in patients with mitral valve disease.
Topics: Aged; Atrial Fibrillation; Female; Heart Failure; Humans; Injections, Intravenous; Middle Aged; Mitr | 1983 |
Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure.
Topics: Aorta; Blood Pressure; Heart; Heart Failure; Heart Rate; Hemodynamics; Humans; Pulmonary Wedge Press | 1983 |
Calcium antagonists in heart failure.
Topics: Aortic Valve Insufficiency; Calcium Channel Blockers; Coronary Disease; Diltiazem; Heart Failure; He | 1983 |
[Calcium antagonists: effects on cardiotoxicity caused by adriamycin. Preliminary trials].
Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Cardiomyopathies; Child; Doxorubicin; Female; Hea | 1983 |
The effects of calcium channel blocking agents on cardiovascular function.
Topics: Angina Pectoris; Animals; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Coronary Disease | 1982 |
[Verapamil in end-stage heart failure due to hypertrophic obstructive cardiopathy].
Topics: Adult; Cardiomyopathy, Hypertrophic; Heart Failure; Hemodynamics; Humans; Male; Verapamil | 1981 |
Verapamil in the treatment of paroxysmal supraventricular tachycardia in infants and children.
Topics: Child; Child, Preschool; Digitalis Glycosides; Drug Interactions; Electrocardiography; Heart Failure | 1981 |
Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure.
Topics: Atrial Fibrillation; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Female; Heart Fa | 1995 |
Use of explanted human hearts as a model for the study of cardiac pathophysiologic conditions.
Topics: Adult; Blood Pressure; Calcium; Cardiomyopathies; Epinephrine; Female; Heart; Heart Failure; Humans; | 1995 |
Toxic effects of diltiazem in a patient with chronic renal failure.
Topics: Acidosis; Adult; Diltiazem; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Failure, Chroni | 1994 |
[Comments on the contribution by G. F. Hauf and H. Roskamm. Heart failure in coronary heart disease].
Topics: Diltiazem; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Verapamil | 1994 |
Calcium channel antagonists. What do the second-generation agents have to offer?
Topics: Arteriosclerosis; Calcium Channel Blockers; Cardiovascular Diseases; Cerebrovascular Disorders; Dihy | 1994 |
Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.
Topics: Amyloidosis; Cardiac Output, Low; Cardiomyopathies; Heart Failure; Humans; Male; Middle Aged; Stroke | 1993 |
New treatment of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Calcium Channel Blockers; Digoxin; Diltiazem; Drug | 1996 |
Pharmacologically induced heart failure for the evaluation of circulatory assistance.
Topics: Anesthetics, Inhalation; Animals; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Cattle; | 1996 |
Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats.
Topics: Animals; Blood Pressure; Brain; Calcium Channel Blockers; Felodipine; Female; Heart; Heart Failure; | 1997 |
Left ventricular spherical dilation and regional contractile dysfunction in dogs with heart failure.
Topics: Animals; Cardiac Pacing, Artificial; Dextrans; Dogs; Heart Failure; Heart Rate; Hemodynamics; Myocar | 1997 |
[KHK and treatment with calcium antagonists].
Topics: Calcium Channel Blockers; Coronary Disease; Heart Failure; Humans; Risk Factors; Vasodilator Agents; | 1996 |
Secondary prevention in acute myocardial infarction. Verapamil is alternative to beta blockers in patients without congestive heart failure.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Heart Failure; Humans; Prognosis; Verapamil | 1998 |
[Verapamil sensitive ventricular tachycardia with myocardial failure in a 2-year-old child].
Topics: Adult; Anti-Arrhythmia Agents; Cardiomyopathies; Child, Preschool; Echocardiography; Electrocardiogr | 1999 |
Angina pectoris, myocardial infarction and verapamil.
Topics: Angina, Unstable; Calcium Channel Blockers; Heart Failure; Humans; Myocardial Infarction; Randomized | 1999 |
[Remission following verapamil use in acromegalic patient with heart failure].
Topics: Acromegaly; Aged; Female; Heart Failure; Humans; Remission Induction; Verapamil | 1999 |
Altered E-C coupling in rat ventricular myocytes from failing hearts 6 wk after MI.
Topics: Animals; Cells, Cultured; Cesium; Heart; Heart Failure; Heart Ventricles; Male; Membrane Potentials; | 2000 |
Dantrolene sodium improves the force-frequency relationship and beta-adregenic responsiveness in failing human myocardium.
Topics: Adrenergic beta-Agonists; Calcium; Calcium Channel Blockers; Dantrolene; Female; Heart Failure; Hear | 1999 |
Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Heart Failure; Hemodynamics; Hypertrophy, Left Ventri | 2001 |
[Left ventricular outflow tract obstruction without left ventricular hypertrophy treated with ACE inhibitors].
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Echocardiography; Female; Heart F | 1999 |
[An elderly case of idiopathic dilatation of the right atrium in which right-sided heart failure was exacerbated by drug-induced bradyarrhythmia].
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Bradycardia; Cardiomegaly; Cardiotonic Agents; Dilatat | 2001 |
L-type Ca(2+) currents overlapping threshold Na(+) currents: could they be responsible for the "slip-mode" phenomenon in cardiac myocytes?
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2002 |
Vitamin C prevents hyperoxia-mediated vasoconstriction and impairment of endothelium-dependent vasodilation.
Topics: Acetylcholine; Adult; Antioxidants; Ascorbic Acid; Blood Flow Velocity; Blood Pressure; Endothelium, | 2002 |
[Iatrogenic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Digitalis Glycosides; Dose-Response Relationship, Drug; Drug The | 1979 |
[Cardiovascular complications during treatment by verapamil. A propos of 6 cases].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Cardiomegaly; Female; Glucagon; Hear | 1975 |
Effect of verapamil in infants with paroxysmal supraventricular tachycardia.
Topics: Drug Evaluation; Heart Failure; Humans; Infant; Infant, Newborn; Injections, Intravenous; Tachycardi | 1979 |
[Treatment of acute left-ventricular insufficiency complicated by tachyarrhythmia under conditions of cardiological emergency service].
Topics: Acute Disease; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Drug Ther | 1979 |
[Effects of calcium antagonists on left ventricular systolic time intervals in patients with artificial pacemakers].
Topics: Aged; Arrhythmias, Cardiac; Calcium; Cardiac Pacing, Artificial; Female; Heart Block; Heart Failure; | 1979 |
[Proceedings: The effect of verapramil (isoptin) on the hemodynamics and size of the acute myocardial infarct].
Topics: Blood Pressure; Cardiac Output; Creatine Kinase; Heart Failure; Heart Rate; Hemodynamics; Humans; My | 1975 |
Incidence of adverse events during treatment with verapamil for suspected acute myocardial infarction.
Topics: Bradycardia; Contraindications; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Myocard | 1992 |
[Combination therapy in chronic heart failure. Hemodynamic effects with a calcium antagonist-diuretic combination].
Topics: Adult; Aged; Chronic Disease; Drug Combinations; Heart Failure; Hemodynamics; Humans; Hydrochlorothi | 1991 |
[Cardiac metastasis as cause of therapy-resistant heart failure].
Topics: Aged; Carcinoma, Papillary; Cardiac Glycosides; Diuretics; Echocardiography; Heart Failure; Heart Ne | 1991 |
The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts.
Topics: Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels; Coronary Circulation; Depressio | 1990 |
Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Resistance; Heart | 1991 |
Different negative inotropic activity of Ca2(+)-antagonists in human myocardial tissue.
Topics: Calcium Channel Blockers; Depression, Chemical; Diltiazem; Heart Atria; Heart Failure; Heart Transpl | 1990 |
Chronic calcium channel blockade prevents the progression of myocardial contractile and electrical dysfunction in the cardiomyopathic Syrian hamster.
Topics: Animals; Calcium Channel Blockers; Cardiomyopathies; Cricetinae; Heart; Heart Failure; Membrane Pote | 1990 |
[The use of propranolol and verapamil in patients with ischemic heart disease].
Topics: Adult; Arrhythmias, Cardiac; Chronic Disease; Coronary Disease; Drug Evaluation; Female; Heart Failu | 1990 |
Intravenous verapamil for tachyarrhythmia in Duchenne's muscular dystrophy.
Topics: Adolescent; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Male; Muscular Dystrophies; T | 1990 |
Continuous verapamil infusion.
Topics: Heart Failure; Humans; Infusions, Intravenous; Tachycardia, Supraventricular; Verapamil | 1989 |
[The efficacy of calcium antagonists in circulatory failure in elderly patients with hypertension].
Topics: Aged; Calcium Channel Blockers; Digoxin; Dose-Response Relationship, Drug; Drug Evaluation; Drug The | 1989 |
[Effects of verapamil on pulmonary arterial pressure in patients with cor pulmonale complicated by heart failure].
Topics: Adult; Aged; Blood Pressure; Female; Heart Failure; Humans; Male; Middle Aged; Pulmonary Artery; Pul | 1989 |
[The use of digoxin, lasix and finoptin in treating circulatory failure in hypertension].
Topics: Aged; Aldosterone; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hy | 1989 |
[Effect of digoxin, furosemide and finoptin on the central hemodynamics in hypertension].
Topics: Aged; Chronic Disease; Digoxin; Drug Evaluation; Drug Therapy, Combination; Female; Furosemide; Hear | 1989 |
Long-acting verapamil and heart failure.
Topics: Aged; Aged, 80 and over; Delayed-Action Preparations; Female; Heart Failure; Humans; Verapamil | 1989 |
Fetal atrial flutter and X-linked dominant vitamin D-resistant rickets.
Topics: Adult; Atrial Flutter; Cesarean Section; Digoxin; Drug Therapy, Combination; Electric Countershock; | 1985 |
Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function.
Topics: Aged; Cardiomegaly; Electrocardiography; Female; Heart Failure; Heart Ventricles; Humans; Hypertensi | 1985 |
Obstetric importance, diagnosis, and management of fetal tachycardias.
Topics: Delivery, Obstetric; Digoxin; Drug Therapy, Combination; Edema; Female; Fetal Diseases; Heart Failur | 1988 |
[Clinical pharmacology of calcium antagonists].
Topics: Aging; Arrhythmias, Cardiac; Biological Availability; Calcium Channel Blockers; Diltiazem; Drug Inte | 1987 |
Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties.
Topics: Anesthesia; Animals; Cardiotonic Agents; Dogs; Female; Heart Failure; Hemodynamics; Hindlimb; Male; | 1987 |
A case of idiopathic sustained ventricular tachycardia of about 70 days' duration.
Topics: Adult; Alcoholism; Electrocardiography; Female; Heart Failure; Humans; Lidocaine; Tachycardia; Verap | 1986 |
Verapamil effects on left ventricular performance in patients with congestive heart failure studied with echocardiography before and after cardiac surgery.
Topics: Adult; Aortic Valve Insufficiency; Depression, Chemical; Echocardiography; Female; Heart; Heart Fail | 1986 |
[Hemodynamic effect of verapamil and nifedipine in chronic heart failure].
Topics: Calcium; Chronic Disease; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Nifedi | 1986 |
[Calcium antagonists in heart failure?].
Topics: Calcium Channel Blockers; Cardiac Output; Diltiazem; Heart Failure; Heart Rate; Hemodynamics; Humans | 1986 |
Experience with calcium antagonist drugs in congestive heart failure.
Topics: Calcium Channel Blockers; Heart Failure; Hemodynamics; Humans; Nifedipine; Vasodilation; Vasodilator | 1987 |
Verapamil preserves adenine nucleotide pool in cardiomyopathic Syrian hamster.
Topics: Adenine Nucleotides; Animals; Body Weight; Collagen; Cricetinae; Disease Models, Animal; Heart Failu | 1986 |
Comparative effects of calcium-channel blocking agents on left ventricular function during acute ischemia in dogs with and without congestive heart failure.
Topics: Animals; Arterial Occlusive Diseases; Calcium Channel Blockers; Coronary Circulation; Coronary Disea | 1985 |
Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia.
Topics: Electric Countershock; Electrocardiography; Female; Heart Arrest; Heart Failure; Hemodynamics; Human | 1985 |
The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetised dog.
Topics: Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Central Venou | 1985 |
[Effect of isoptin on the hemodynamics of patients with circulatory insufficiency].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Heart Failure; Hemodynamics; Humans; Middle Aged; Vascu | 1985 |
Transplacental treatment of tachycardia-induced fetal heart failure with verapamil and amiodarone: a case report.
Topics: Adult; Amiodarone; Benzofurans; Female; Fetal Diseases; Fetal Heart; Heart Failure; Heart Rate; Huma | 1985 |
[Effect of verapamil and nifedipine on the fractional composition of calcium in the blood serum].
Topics: Calcium; Female; Heart Failure; Male; Nifedipine; Verapamil | 1985 |
Reversal of verapamil-, dichloroisoproterenol-, and propranolol-induced cardiac failure by histamine.
Topics: Animals; Blood Pressure; Cardiac Output; Depression, Chemical; Female; Guinea Pigs; Heart Atria; Hea | 1974 |
[Intravenous long-term inhibition of labor using beta-mimetics and blocking of side effects].
Topics: Adrenergic beta-Agonists; Adult; Female; Fever; Heart Failure; Humans; Obstetric Labor, Premature; P | 1971 |
[Gradulon and gradulon s. T. in the treatment of heart diseases of various causes in the daily practice].
Topics: Arrhythmias, Cardiac; Benzoates; Coronary Disease; Digoxin; Drug Combinations; Heart Diseases; Heart | 1972 |
[Fatal outcome after intravenous application of isoptin].
Topics: Drug Hypersensitivity; Electrocardiography; Heart Failure; Humans; Injections, Intravenous; Middle A | 1972 |
Verapamil in cardiac dysrhythmias during anaesthesia.
Topics: Adolescent; Adult; Aged; Anesthesia, Inhalation; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhythm | 1970 |
[On the clinical trial of a heart and coronary drug].
Topics: Adult; Aged; Cardiac Glycosides; Coronary Disease; Heart Diseases; Heart Failure; Humans; Middle Age | 1968 |